Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023
21 Septembre 2023 - 7:30AM
Business Wire
- Sensorion to host a webconference dedicated to shareholders
on September 25th, 2023, in French, at 6am ET (12pm CET)
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat, and prevent
within the field of hearing loss disorders, is pleased to announce
it is hosting a webconference on September 25, 2023, and its
participation in two upcoming investor conferences in October
2023.
Sensorion’s CEO, Nawal Ouzren, and management team will host a
webconference dedicated to shareholders, in French, on
September 25, 2023, at 6am ET (12pm CET), to comment on the
Company's latest activities and outlook.
Click here to join the meeting Meeting
ID: 377 992 162 784 Secret code: gtEzYU
You will also be able to join the webconference from Sensorion’s
website.
Nawal Ouzren will attend, in-person, Chardan’s 7th Annual
Genetic Medicines Conference, held on October 2-3, 2023, in
New-York City, USA. On that occasion, Nawal will participate in a
fireside chat with analyst Geulah Livshits on October 3, 2023, at
8am ET. Sensorion’s CEO will also be available for one-on-one
meetings throughout the conference.
Nawal Ouzren will participate, in-person, in the HealthTech
Innovation Days (HTID) that will take place on October 24-25,
2023, in Paris, France. Nawal will be available for one-on-one
meetings throughout the conference.
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which
specializes in the development of novel therapies to restore, treat
and prevent hearing loss disorders, a significant global unmet
medical need. Sensorion has built a unique R&D technology
platform to expand its understanding of the pathophysiology and
etiology of inner ear related diseases, enabling it to select the
best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary
monogenic forms of deafness, developed in the framework of its
broad strategic collaboration focused on the genetics of hearing
with the Institut Pasteur. OTOF-GT targets deafness caused by
mutations of the gene encoding for otoferlin and GJB2-GT targets
hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The
Company is also working on the identification of biomarkers to
improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders.
Sensorion’s clinical-stage portfolio includes one Phase 2
product: SENS-401 (Arazasetron) progressing in a planned Phase 2
proof of concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
2022 full year financial report published on March 30, 2023, and
available on our website and to the development of economic
conditions, financial markets, and the markets in which Sensorion
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Sensorion or not
currently considered material by Sensorion. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance, or achievements of Sensorion to be
materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230920422582/en/
Investor Relations Noémie Djokovic, Investor Relations
and Communication Associate ir.contact@sensorion-pharma.com
Press Relations Ulysse Communication Pierre-Louis Germain
/ 00 33 (0)6 64 79 97 51 plgermain@ulysse-communication.com
Bruno Arabian / 00 00(0)6 87 88 47 26
barabian@ulysse-communication.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024